COLLEGE OF MEDICINE AND HEALTH
Medicine, Nursing and Allied Health Professions

Loading content
Dr Timothy McDonald

Dr Timothy McDonald

Consultant Clinical Scientist/ Honorary Clinical Associate Professor

 8250

 +44 (0) 1392 728250

 

Overview

Dr McDonald has worked in NHS Blood Sciences for the last 15 years and is a consultant clinical scientist at the Royal Devon and Exeter Hospital.

 He holds an NIHR Senior Clinical Lecturer fellowship and is the lead scientist coordinating the central laboratory on the DIRECT study – a €40million EU Innovative Medicines Initiative grant on stratification of treatment in Type 2 diabetes.

Broad research specialisms

His broad research interest is the stratification and correct diagnosis of patients with diabetes.

Qualifications

BSc, PgC, MSc, PhD, FRCPath

Research

Research interests

Dr McDonald's research interest involve using biomarkers to identify patients with monogenic forms of diabetes. They have developed clinical predication models to help clinicians identify patients with rare genetic causes of diabetes. The advantage being that these patients can often be treated with tablets, rather than insulin injections.

Assessment of endogenous insulin production is another area of active research. They have investigated the possibility of measuring C-peptide in urine rather than in a blood sample, identifying the clinical utility and optimal storage parameters that enable measurement from a posted urine sample. The measurement of urinary C-peptide/Creatinine ratio (UCPCR) is now provided as a routine NHS pathology test to assess endogenous insulin secretion and is requested by over 100nclinical laboratories in the UK.

In 2012, He was awarded the Department of Health’s Young Healthcare Scientist of the year award for translational research and the ACB professors prize in 2016.

Research projects

  • DIRECT (EU IMI funded project)– identifying biomarkers and clinical variables to identify repid glycaemic deteriation and variable treatment response in type 2 diabetes
  • MASTERMIND (MRC funded)- Stratification of treatment response in type 2 diabetes.

Grants/Funding

  • NIHR CSO Fellowship 2013-2017 (£250,000)
  • RD&E project grant £9000
  • ACB small project grant £3000

Research grants

  • 2017 NIHR Faculty
    NIHR Senior Clinical Lectureship
  • 2016 Diabetes UK
    .
  • 2016 Helmsley Foundation
    .
  • 2015 Diabetes, UK.
    Equipment Grant: Single tube diagnosis and classification of diabetes, £21,375
  • 2012 National Institute for Health Research
    Integration of multi-disciplinary pathology investigations and clinical characteristics to improve targeted genetic testing for MODY (maturity onset diabetes of the young) NIHR
  • 2012 EU-IMI
    Diabetes REseraCh on patient stratification (DIRECT)
  • 2010 Association of Clinical Biochemists
    Assay Development grant
  • 0 Juvenile Diabetes Research Foundation
    Reference 3-SRA-2014-314-M-R $1.1 million(Co-PI)

Publications

Key publications | Publications by category | Publications by year

Key publications


Flanagan SE, Haapaniemi E, Russell MA, Caswell R, Allen HL, De Franco E, McDonald TJ, Rajala H, Ramelius A, Barton J, et al (2014). Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet, 46(8), 812-814. Abstract.  Author URL.  Full text.
McDonald TJ, Warren RE (2014). Diagnostic confusion? Repeat HbA1c for the diagnosis of diabetes. DIABETIC MEDICINE, 31, 72-72. Author URL.
McDonald TJ, Warren R (2014). Diagnostic confusion? Repeat HbA1c for the diagnosis of diabetes. Diabetes Care, 37(6), e135-e136. Author URL.
Koivula RW, Heggie A, Barnett A, Cederberg H, Hansen TH, Koopman AD, Ridderstråle M, Rutters F, Vestergaard H, Gupta R, et al (2014). Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia
McDonald TJ (2014). The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 57(1), 187-191. Abstract.
McDonald TJ, McEneny J, Pearson ER, Thanabalasingham G, Szopa M, Shields BM, Ellard S, Owen KR, Malecki MT, Hattersley AT, et al (2012). Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes. Clin Chim Acta, 413(9-10), 927-932. Abstract.  Author URL.

Publications by category


Journal articles

Grubb A, McDonald T, Rutters F, Donnelly L, Hattersley A, Oram R, Palmer C, van der Heijden A, Carr F, Elders P, et al (In Press). A Type 1 Diabetes Genetic Risk Score can identify patients with GAD65 autoantibody positive type 2 diabetes that rapidly progress to insulin therapy. Diabetes Care Full text.
Knight AR, Taylor EL, Lukaszewski R, Winyard PG (In Press). A high-sensitivity electrochemiluminescence-based ELISA for the measurement of the oxidative stress biomarker, 3-nitrotyrosine, in human blood serum and cells. Free Radical Biology and Medicine Full text.
Williams GM, Long AE, Wilson IV, Aitken RJ, Wyatt RC, McDonald TJ, Wong FS, Hattersley AT, Williams AJK, Bingley PJ, et al (In Press). Beta cell function and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes. Diabetologia, 59(12), 2722-2726. Abstract.  Author URL.  Full text.
Shields B, McDonald T, Oram R, Hill A, Hudson M, Leete P, Pearson E, Richardson S, Morgan N, Hattersley A, et al (In Press). C-peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subsequent stable phase. Diabetes Care Full text.
Jones AG, McDonald TJ (In Press). Comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4 and -5 trials". Diabetes Obes Metab, 20(6), 1549-1550. Author URL.
Johnson MB, Flanagan SE, Martins TB, Hill HR, Hattersley AT, McDonald TJ (In Press). Low IgE is a Useful Tool to Identify STAT3 Gain-of-Function Mutations. Clin Chem, 62(11), 1536-1538. Author URL.  Full text.
Jones AG, mcdonald TJ, Shields BM, Hill AV, Hyde CJ, Knight BA, Hattersley AT (In Press). Markers of beta cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care Full text.
Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG (In Press). Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabet Med, 33(11), 1554-1558. Abstract.  Author URL.  Full text.
Shepherd M, Shields B, Hammersley S, Hudson M, McDonald TJ, Colclough K, Oram RA, Knight B, Hyde C, Cox J, et al (In Press). Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population with Monogenic Diabetes. Diabetes Care, 39(11), 1879-1888. Abstract.  Author URL.  Full text.
Johnson MBJ, Patel K, De Franco E, Houghton J, McDonald T, Ellard S, Flanagan S, Hattersley A (2018). A Type 1 diabetes genetic risk score can discriminate monogenic autoimmunity with diabetes from early onset clustering of polygenic autoimmunity with diabetes. Diabetologia Full text.
Clissold RL, Fulford J, Hudson M, Shields BM, McDonald TJ, Ellard S, Hattersley AT, Bingham C (2018). Exocrine pancreatic dysfunction is common in hepatocyte nuclear factor 1β-associated renal disease and can be symptomatic. Clin Kidney J, 11(4), 453-458. Abstract.  Author URL.  Full text.
Walker GJ, Moore L, Heerasing N, Hendy P, Perry MH, McDonald TJ, Debenham T, Bethune R, Bewshea C, Hyde C, et al (2018). Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Aliment Pharmacol Ther, 47(8), 1103-1116. Abstract.  Author URL.
Dennis J, Shields B, Hill A, Knight B, McDonald T, Rodgers L, Weedon M, Henley W, Sattar N, Holman R, et al (2018). Precision medicine in Type 2 diabetes: Clinical markers of insulin resistance are associated with altered short and long-term glycemic response to DPP4-inhibitor therapy. Diabetes Care Full text.
Teare HJA, de Masi F, Banasik K, Barnett A, Herrgard S, Jablonka B, Postma JWM, McDonald TJ, Forgie I, Chmura PJ, et al (2018). The governance structure for data access in the DIRECT consortium: an innovative medicines initiative (IMI) project. Life Sci Soc Policy, 14(1). Abstract.  Author URL.
Patel KA, Weedon MN, Shields BM, Pearson ER, Hattersley AT, McDonald TJ, UNITED study team (2018). Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score can Exclude Individuals with Type 1 Diabetes from Inappropriate Genetic Testing for Monogenic Diabetes. Diabetes Care Author URL.
Chakera AJ, McDonald TJ, Knight BA, Vaidya B, Jones AG (2017). Current laboratory requirements for adrenocorticotropic hormone and renin/aldosterone sample handling are unnecessarily restrictive. Clin Med (Lond), 17(1), 18-21. Abstract.  Author URL.  Full text.
Shields B, Shepherd M, Hudson M, McDonald T, Colclough K, Peters J, Knight B, Hyde C, Ellard S, Pearson E, et al (2017). Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care Full text.
Davidson J, McDonald T, Sutherland C, Mostazir M, VanAalten L, Wilkin T (2017). Proinsulin is stable at room temperature for 24 hours in EDTA: a clinical laboratory analysis (adAPT 3). PLoS One, 12(4). Abstract.  Author URL.  Full text.
Hope SV, Knight BA, Shields BM, Hill AV, Choudhary P, Strain WD, McDonald TJ, Jones AG (2017). Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia Full text.
McDonald TJ, Besser RE, Perry M, Babiker T, Knight BA, Shepherd MH, Ellard S, Flanagan SE, Hattersley AT (2017). Screening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement. Diabetologia, 60(11), 2168-2173. Abstract.  Full text.
(2017). Tests aiding diagnosis of monogenic diabetes. Practical Diabetes, 34(6), 217-220a.
Oram RA, Patel K, Hill A, Shields B, McDonald TJ, Jones A, Hattersley AT, Weedon MN (2016). A Type 1 Diabetes Genetic Risk Score can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes Care, 39(3), 337-344. Abstract.  Author URL.  Full text.
Perry M, O'Connor J, James AJ, Cudmore AP, Lewis AV, Salzmann MB, McDonald TJ (2016). A cautionary tale: Unforeseen consequences of lean processing in a blood sciences laboratory. Clin Biochem, 49(16-17), 1311-1312. Author URL.
McDonald TJ, Perry MH (2016). Detection of C-Peptide in Urine as a Measure of Ongoing Beta Cell Function. Methods Mol Biol, 1433, 93-102. Abstract.  Author URL.
Seelig E, Timper K, Falconnier C, Stoeckli R, Bilz S, Oram R, McDonald TJ, Donath MY (2016). Interleukin-1 antagonism in type 1 diabetes of long duration. Diabetes Metab, 42(6), 453-456. Author URL.
McDonald TJ, Besser REJ, Perry MH, Babiker T, Hattersley AT (2016). Newborn screening by blood spot glucose can diagnose neonatal diabetes at day 5 of life. DIABETIC MEDICINE, 33, 73-73. Author URL.
Parfitt C, Church D, Armston A, Couchman L, Evans C, Wark G, McDonald TJ (2015). Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues. CLINICAL BIOCHEMISTRY, 48(18), 1354-1357. Author URL.
Perry M, Bewshea C, Brown R, So K, Ahmad T, McDonald T (2015). Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. Ann Clin Biochem, 52(Pt 6), 672-674. Abstract.  Author URL.
McDonald TJ, Oram RA, Vaidya B (2015). Investigating hyperkalaemia in adults. BMJ, 351 Author URL.
Oram RA, McDonald TJ, Shields BM, Hudson MM, Shepherd MH, Hammersley S, Pearson ER, Hattersley AT, UNITED Team (2015). Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care, 38(2), 323-328. Abstract.  Author URL.  Full text.
McDonald TJ, Oram RA, Vaidya B (2015). RATIONAL TESTING Investigating hyperkalaemia in adults. BMJ-BRITISH MEDICAL JOURNAL, 351 Author URL.
(2015). Systolic blood pressure control among individuals with type 2 diabetes: a comparative effectiveness analysis of three interventions. American Journal of Hypertension, 28(8), 995-1009. Abstract.
(2014). Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nature Genetics, 46(8), 812-814. Abstract.
Flanagan SE, Haapaniemi E, Russell MA, Caswell R, Allen HL, De Franco E, McDonald TJ, Rajala H, Ramelius A, Barton J, et al (2014). Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet, 46(8), 812-814. Abstract.  Author URL.  Full text.
McDonald TJ, Warren RE (2014). Diagnostic confusion? Repeat HbA1c for the diagnosis of diabetes. DIABETIC MEDICINE, 31, 72-72. Author URL.
McDonald TJ, Warren R (2014). Diagnostic confusion? Repeat HbA1c for the diagnosis of diabetes. Diabetes Care, 37(6), e135-e136. Author URL.
Vestergaard H, Gupta R, Herrgård S, Heymans MW, Perry MH, Rauh S, Siloaho M, Teare HJA, Thorand B, Bell J, et al (2014). Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: Rationale and design of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 57(6), 1132-1142. Abstract.
Koivula RW, Heggie A, Barnett A, Cederberg H, Hansen TH, Koopman AD, Ridderstråle M, Rutters F, Vestergaard H, Gupta R, et al (2014). Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia
(2014). Effect of the holiday season in patients with diabetes: Glycemia and lipids increase postholiday, but the effect is small and transient. Diabetes Care, 37(5).
Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, Brown RJ, Hattersley AT, McDonald TJ (2014). Erratum to: the majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 57(1). Author URL.
Myngheer N, Allegaert K, Hattersley A, McDonald T, Kramer H, Ashcroft FM, Verhaeghe J, Mathieu C, Casteels K (2014). Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes. Diabetes Care, 37(12), 3333-3335. Abstract.  Author URL.
Oram RA, Brooks AM, Forbes S, Eckoldt S, Smith RM, Choudhary P, Rosenthal MJ, Johnson P, Rutter MK, Burling KA, et al (2014). Home urine C-peptide creatinine ratio can be used to monitor islet transplant function. Diabetes Care, 37(6), 1737-1740. Abstract.  Author URL.
Aitken RJ, Wilson IV, Long AE, Williams AJK, McDonald TJ, Gillespie KM, Wong FS, Hattersley AT, Bingley PJ (2014). Residual beta cell function in long-standing childhood onset Type 1 diabetes. DIABETIC MEDICINE, 31, 19-20. Author URL.
Hamilton AJ, Bingham C, McDonald TJ, Cook PR, Caswell RC, Weedon MN, Oram RA, Shields BM, Shepherd M, Inward CD, et al (2014). The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a β cell phenotype. J Med Genet, 51(3), 165-169. Abstract.  Author URL.  Full text.
Adamson K, Nayak AU, Khurana R, Hunter SJ, Ali A, Au S, Ryder REJ (2014). The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study. Diabetic Medicine, 31(4), 403-411. Abstract.
McDonald TJ (2014). The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 57(1), 187-191. Abstract.
Jones AG, Hill AV, Stewart J, Githens-Mazer G, Shields BM, McDonald TJ, Knight BA, Hattersley AT (2013). Baseline HbA1c is the major clinical predictor of glycaemic response to incretin based agents in Type 2 diabetes. DIABETIC MEDICINE, 30, 164-164. Author URL.
Nowak N, Szopa M, Thanabalasingham G, McDonald TJ, Colclough K, Skupien J, James TJ, Kiec-Wilk B, Kozek E, Mlynarski W, et al (2013). Cystatin C is not a good candidate biomarker for HNF1A-MODY. ACTA DIABETOLOGICA, 50(5), 815-820. Author URL.
Besser REJ, Shields BM, Hammersley SE, Colclough K, McDonald TJ, Gray Z, Heywood JJN, Barrett TG, Hattersley AT (2013). Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes. Pediatr Diabetes, 14(3), 181-188. Abstract.  Author URL.
Mericq V, Hassing J, Richmond EJ, Martin WR, Acerini C, Kaulfers AM, Flynn DP, Popovic J, Sperling MA, Hussain K, et al (2013). Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: Expanding the clinical phenotype. Diabetologia, 56(1), 218-221.
Flanagan SE, Mackay DJG, Greeley SAW, McDonald TJ, Mericq V, Hassing J, Richmond EJ, Martin WR, Acerini C, Kaulfers AM, et al (2013). Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: expanding the clinical phenotype. Diabetologia, 56(1), 218-221. Author URL.
Oram RA, McDonald TJ, Vaidya B (2013). Investigating hypokalaemia. BMJ, 347 Author URL.
McDonald TJ, Ellard S (2013). Maturity onset diabetes of the young: identification and diagnosis. Ann Clin Biochem, 50(Pt 5), 403-415. Abstract.  Author URL.
Steele AM, Wensley KJ, Brewer E, Shields BM, Hattersley AT, McDonald TJ (2013). Preanalytical sample handling of venous blood: How to ensure your glucose measurement is accurate and reliable. Practical Diabetes, 30(3), 128-131. Abstract.
Thong KY, Mcdonald TJ, Hattersley AT, Blann AD, Ramtoola S, Duncan C, Carr S, Adamson K, Nayak AU, Khurana R, et al (2013). The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study. Diabetic Medicine
(2013). Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabetic Medicine, 30(11), 1342-1348. Abstract.
Hope SV, Jones AG, Goodchild E, Shepherd M, Besser REJ, Shields B, McDonald T, Knight BA, Hattersley A (2013). Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabet Med, 30(11), 1342-1348. Abstract.  Author URL.  Full text.
Oram RA, Rawlingson A, Shields BM, Bingham C, Besser REJ, McDonald TJ, Knight BA, Hattersley AT (2013). Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. BMJ Open, 3(12). Abstract.  Author URL.  Full text.
Oram RA, Brooks AMS, Smith R, Rutter MK, Johnson PR, Choudhary P, Rosenthal M, Forbes S, McDonald TJ, Hattersley AT, et al (2013). Urine c-peptide creatinine ratio can be used for home monitoring of islet transplant function. DIABETIC MEDICINE, 30, 87-87. Author URL.
Knight BA, Hattersley AT (2012). Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocrine Disorders, 12 Abstract.  Full text.
McDonald TJ, Perry MH, Peake RWA, Pullan NJ, O'Connor J, Shields BM, Knight BA, Hattersley AT (2012). EDTA improves stability of whole blood C-peptide and insulin to over 24 hours at room temperature. PLoS One, 7(7). Abstract.  Author URL.
(2012). Lipoprotein composition in HNF1A-MODY: Differentiating between HNF1A-MODY and Type 2 diabetes. Clinica Chimica Acta, 413(9-10), 927-932. Abstract.
McDonald TJ, McEneny J, Pearson ER, Thanabalasingham G, Szopa M, Shields BM, Ellard S, Owen KR, Malecki MT, Hattersley AT, et al (2012). Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes. Clin Chim Acta, 413(9-10), 927-932. Abstract.  Author URL.
Shields BM, McDonald TJ, Ellard S, Campbell MJ, Hyde C, Hattersley AT (2012). The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia, 55(5), 1265-1272. Abstract.  Author URL.
Thomas NJ, Shields BM, Besser REJ, Jones AG, Rawlingson A, Goodchild E, Leighton C, Bowman P, Shepherd M, Knight BA, et al (2012). The impact of gender on urine C-peptide creatinine ratio interpretation. Ann Clin Biochem, 49(Pt 4), 363-368. Abstract.  Author URL.
Besser REJ, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2012). The impact of insulin administration during the mixed meal tolerance test. Diabet Med, 29(10), 1279-1284. Abstract.  Author URL.
(2012). Using highly sensitive C-reactive protein measurement to diagnose MODY in a family with suspected type 2 diabetes. BMJ Case Reports Abstract.
Besser REJ, Jones J, McDonald TJ, Smith R, Shepherd MH, Hattersley AT (2012). Using highly sensitive C-reactive protein measurement to diagnose MODY in a family with suspected type 2 diabetes. BMJ case reports, 2012 Abstract.
Bowman P, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2012). Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes. Diabet Med, 29(1), 90-93. Abstract.  Author URL.
(2011). A novel case of a raised testosterone and LH in a young man. Clinica Chimica Acta, 412(21-22), 1999-2001. Abstract.
McDonald TJ, Shields BM, Lawry J, Owen KR, Gloyn AL, Ellard S, Hattersley AT (2011). High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care, 34(8), 1860-1862. Abstract.  Author URL.
McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P, Williams A, Hattersley AT, Ellard S (2011). Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med, 28(9), 1028-1033. Abstract.  Author URL.
(2011). Response to comment on: McDonald et al. High-Sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care 2011;34: 1860-1862. Diabetes Care, 34(12).
Besser REJ, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S, Hattersley AT (2011). Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care, 34(2), 286-291. Abstract.  Author URL.
Besser REJ, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011). Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care, 34(3), 607-609. Abstract.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Shields BM, Hope SV, Bowman P, Oram RA, Knight BA, Hattersley AT (2011). Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. Diabet Med, 28(9), 1034-1038. Abstract.  Author URL.
(2009). Health promotion strategies for the "boomer" generation: Wellness for the mature worker. American Journal of Health Promotion, 23(3), 1-9.
McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB, Hattersley AT (2009). Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem, 55(11), 2035-2039. Abstract.  Author URL.
Anand S, Cracknell B, Cukierman-Yaffe T, Gafni A, Guyatt G, Hall S, Kaszyca J, Lonn E, McLeod D, Read K, et al (2008). Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine, 358(24), 2545-2559. Abstract.
Miller A, Edington DW (2006). Association of healthcare costs with per unit body mass index increase. Journal of Occupational and Environmental Medicine, 48(7), 668-674. Abstract.
(2006). Participation in employer-sponsored wellness programs before and after retirement. American Journal of Health Behavior, 30(1), 27-38. Abstract.
(2005). BMI, physical activity, and health care utilization/costs among medicare retirees. Obesity Research, 13(8), 1450-1457. Abstract.
Edington DW (2004). Association of Additional Health Risks on Medical Charges and Prevalence of Diabetes Within Body Mass Index Categories. American Journal of Health Promotion, 18(3), 264-268. Abstract.
Napier D, Galante S, Smith T, Edington DW (2004). Comparing excess costs across multiple corporate populations. Journal of Occupational and Environmental Medicine, 46(9), 937-945. Abstract.
(2004). Relationship of Body Mass Index and Physical Activity to Health Care Costs among Employees. Journal of Occupational and Environmental Medicine, 46(5), 428-436. Abstract.
(2003). Association Between Wellness Score from a Health Risk Appraisal and Prospective Medical Claims Costs. Journal of Occupational and Environmental Medicine, 45(10), 1049-1057. Abstract.
Musich S, McDonald T, Hirschland D, Edington DW (2003). Erratum: Examination of risk status transitions among active employees in a comprehensive worksite health promotion program (Journal of Occupational and Environmental Medicine (April)). Journal of Occupational and Environmental Medicine, 45(6).
(2003). Examination of risk status transitions among active employees in a comprehensive worksite health promotion program. Journal of Occupational and Environmental Medicine, 45(4), 393-399. Abstract.
Edington DW (2003). Pattern of Medical Charges after Quitting Smoking among those with and without Arthritis, Allergies, or Back Pain. American Journal of Health Promotion, 18(2), 133-142. Abstract.
(2003). The relationship between National Heart, Lung, and Blood Institute weight guidelines and concurrent medical costs in a manufacturing population. American Journal of Health Promotion, 17(3), 183-189. Abstract.
Musich S, McDonald T, Hirschland D, Edington DW (2002). Excess healthcare costs associated with excess health risks in diseased and non-diseased Health Risk Appraisal participants. Disease Management and Health Outcomes, 10(4), 251-258. Abstract.
Edington DW (2002). Influence of participation in a worksite health-promotion program on disability days. Journal of Occupational and Environmental Medicine, 44(8), 776-780. Abstract.
(2001). Changes in health risks among the participants in the United Auto Workers - General Motors lifesteps health promotion program. American Journal of Health Promotion, 16(1), 7-15. Abstract.
(2001). Internal associations among health-risk factors and risk prevalence. American Journal of Health Behavior, 25(4), 407-417. Abstract.
(2001). Self-reported utilization of preventive health services by retired employees age 65 and older. Journal of the American Geriatrics Society, 49(12), 1665-1672. Abstract.

Chapters

(2013). Diabetes Mellitus. In  (Ed) The Immunoassay Handbook, 783-794.
McDonald TJ (2013). The Immunoassay Handbook. In Wild D (Ed) The Immunoassay Handbook, Gulf Professional Publishing. Abstract.

Conferences

Hammersley SE, Bolt RL, Hill AV, McDonald TJ, Oram RA, Hattersley AT (2017). A novel patient focused approach enables study participation and aids recruitment rate in Type 1 diabetes research.  Author URL.
Oram RA, Leete P, Shields B, Richardson S, Hill A, McDonald T, Morgan N, Hattersley A (2017). C-peptide measurements support the existence of two distinct subtypes of Type 1 diabetes as defined by pancreatic immunopathology.  Author URL.
Dennis JM, Shields BM, Henley WE, Knight BA, McDonald TJ, Hill AV, Weedon MN, Rodgers LR, Hattersley AT, Jones AG, et al (2017). Clinical markers of insulin resistance predict reduced glycaemic response with DPP4-inhibitors: a MASTERMIND stratified medicine study.  Author URL.
Shields B, Richardson S, Oram R, Leete P, Hill A, McDonald T, Morgan N, Hattersley A (2017). Cross-sectional c-peptide data and histological analysis of pancreas samples suggest two phases of beta cell decline in Type 1 diabetes.  Author URL.  Full text.
Grubb AL, Patel KA, Oram RA, Hill AV, Angwin C, McDonald TJ, Weedon MN, Hattersley AT, Shields BV, Jones AG, et al (2017). Development of a risk calculator to identify patients with Type 1 diabetes who will require early insulin therapy.  Author URL.
Dawed AY, Mari A, McDonald TJ, Hong MG, Sharma S, Robertson NR, Mahajan A, Walker M, Gough S, Zhou K, et al (2017). GLP-1 receptor variants markedly differentiate glycaemic response to GLP-1 receptor agonists: a DIRECT study.  Author URL.
Hope SV, Knight BA, Shields BM, Hill A, Choudhary P, Strain WD, Hattersley AT, McDonald TJ, Jones G (2017). RANDOM NON-FASTING C-PEPTIDE CAN BE USED AS a RISK ASSESSMENT TOOL FOR HYPOGLYCAEMIA IN ELDERLY NSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES.  Author URL.
Juszczak A, James TJ, McDonald TJ, Vaxillaire M, Klimes I, Malecki MT, Hansen T, Njolstad PR, Tuomi T, Gloyn AL, et al (2016). Assessing the likely function of HNF1A missense variants using CRP and allele frequency data.  Author URL.
Patel KA, Oram RA, Mcdonald TJ, Hudson M, Colclough K, Ellard S, Weedon MN, Pearson EZ, Hattersley AT (2016). Classifying the unclassified using Type 1 diabetes genetic risk score: patients with young onset diabetes who are islet autoantibody negative and have preserved c-peptide.  Author URL.
Dawed AY, Jones AG, McDonald TJ, Walker M, Mari A, Franks PW, Pearson ER, Project IMI-DIRECT (2016). Determinants of glucagon secretion in prediabetes and recently diagnosed type 2 diabetes: an IMI-DIRECT study.  Author URL.
Oram RA, Hammersley S, Hill A, Shields B, Hattersley A, McDonald T (2016). Longitudinal study of extremely low c-peptide: evidence for persistent beta cells in all people with Type 1 diabetes.  Author URL.
Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG (2016). Random non-fasting c-peptide provides an accurate measure of endogenous insulin secretion for clinical practice.  Author URL.
Umapathysivam MM, McDonald T, Humphreys S, Neville M, Gloyn AL, McCarthy MI, Hattersley AT, Karpe F, Frayling TM (2016). Strategies for improving statistical power for detailed physiological characterisation of individuals with type 2 diabetes-associated variants.  Author URL.
Peters JL, Anderson R, Shields BM, King S, Hudson M, Shepherd M, McDonald TJ, Pearson E, Hattersley AT, Hyde C, et al (2016). Strategies to identify individuals with MODY: results of a health economic model.  Author URL.
Craig ZV, Hill AV, McDonald TJ, Hattersley AT, Jones AG, Shields BM (2016). Time to change the HbA1c cut-off for prediabetes.  Author URL.
Weedon MN, Hill AV, McDonald TJ, Patel KA, Jones A, Hattersley AT, Oram R (2015). A novel inexpensive test can discriminate between Type 1 and Type 2 diabetes.  Author URL.
Mcdonald TJ, Parfitt C, Armston A, Church D, Couchman L, Evans C, Wark G (2015). Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues.  Author URL.
Veale DA, McCulloch RW, McDonald TJ, Cudmore A, Parfitt C, O'Connor J, Kerr JP (2015). Current use of nephelometric quantification of serum free light chains (FLCs) in the management of plasma cell dyscrasias, and the potential benefits of point-of-care testing.  Author URL.
Jones AG, Hill AV, Bolt R, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2015). Insulin resistance and high fasting glucose are associated with reduced glycaemic response to dipeptidyl peptidase 4 (DPP-4) inhibitor therapy.  Author URL.
Hope SV, McDonald TJ, Hill AV, Strain WD, Hattersley AT (2015). Low c-peptide is associated in insulin-treated patients with hypoglycaemia unawareness as well as hypoglycaemia frequency.  Author URL.
Rodgers LR, Pearson ER, Angwin CD, Hammersley S, McDonald TJ, Shields BM, Hattersley AT, Jones AG, Consortium M (2015). Response to glucose lowering therapy can be assessed by a brief period of treatment withdrawal: a MASTERMIND study.  Author URL.
Chapman DP, Gooding KM, McDonald TJ, Anning CM, Pamphilon N, Ball C, Casanova F, Shore AC (2015). Using clinical characteristics to account for variation of urinary creatinine excretion improves the accuracy of the albumin to creatinine ratio (ACR) to identify individuals with microalbuminuria.  Author URL.
Oram RA, McDonald TJ, Shields BM, Pearson ER, Hattersley AT, Team UNITEDR (2014). A large, population-based study demonstrates that most people with long duration Type 1 diabetes are insulin microsecretors and produce their own endogenous insulin.  Author URL.
Flanagan SE, Haapaniemi E, Russell MA, McDonald TJ, Barton J, Murphy NP, Seppanen M, Milenkovic T, Heiskanen K, Lernmark A, et al (2014). A novel syndrome of early-onset type 1 diabetes and multi-organ autoimmunity caused by activating germline mutations in STAT3.  Author URL.
Shields BM, Hudson M, Shepherd M, Oram R, McDonald TJ, Ellard S, Pearson ER, Hattersley AT, Team UNITED (2014). Comparison of screening using clinical criteria and biomarkers to identify maturity-onset diabetes of the young (MODY) in a community based setting.  Author URL.
Jones AG, Shields BM, Hill AV, McDonald TJ, Knight BA, Hattersley AT (2014). Defining good response to glucose lowering therapy: different definitions identify different individuals and associated characteristics.  Author URL.
Jones AG, McDonald TJ, Hill AV, Stewart J, Shields BM, Knight BA, Hattersley AT (2014). Markers of beta cell failure are associated with reduced glycaemic response to GLP-1 agonists in Type 2 diabetes.  Author URL.
McDonald TJ, Oram R, Shields B, Pearson E, Hattersley A (2014). Most people with long duration of type 1 diabetes are insulin microsecretors and produce their own endogenous insulin.  Author URL.
Shepherd M, Shields B, Knight B, Weinand-Barnett S, Fox CJ, McDonald TJ, Hattersley AT (2014). Patients with Type 2 diabetes treated with analogue insulin require 40% more insulin to achieve the same level of HbA1c than those on non-analogue insulin.  Author URL.
Bingley PJ, Aitken RJ, Wilson IV, Long AE, Williams AJK, McDonald T, Wong S, Hattersley AT, Gillespie KM (2014). Residual beta cell function in long-standing childhood onset type 1 diabetes.  Author URL.
Hudson MM, Shepherd M, Oram RA, McDonald TJ, Ellard S, Shields BM, Hattersley AT, Team UR (2013). A population-based approach to genetic testing defines the prevalence of maturity onset diabetes of the young (MODY) in patients with diabetes diagnosed under 30 years as 3%.  Author URL.
Jones AG, Hill AV, Stewart J, Shields BM, McDonald TJ, Knight BA, Hattersley AT (2013). Markers of insulin resistance and beta cell function do not predict response to incretin based treatments in type 2 diabetes.  Author URL.
Hammersley S, Oram R, Shepherd M, Moudiotis C, Fraser B, Mallam K, Cox J, Smith B, McDonald TJ, Besser REJ, et al (2013). Prevalence of non-Type 1 diabetes in paediatric diabetes.  Author URL.
Oram RA, McDonald TJ, Jones AG, Besser REJ, Hattersley AT (2013). The majority of patients with over five years of Type 1 diabetes are insulin microsecretors and have functioning beta cells.  Author URL.  Full text.
Hope SV, Jones AG, Shepherd M, Shields B, Strain D, McDonald T, Knight BA, Hattersley AT (2013). Urinary C-peptide creatinine ratio to detect absolute insulin deficiency in type 2 diabetes.  Author URL.
Shields BM, McDonald TJ, Owen KR, Malecki MT, Besser REJ, Jones AG, Ellard S, Hattersley AT (2012). Integration of biomarkers and clinical characteristics provides the best method for identifying patients with MODY.  Author URL.
Oram RA, Shepherd MH, Hudson M, Sanders T, Tiley S, Hammersley S, Shields B, McDonald TJ, Knight BA, Besser REJ, et al (2012). The prevalence of endogenous insulin production in a cohort of adults with type 1 diabetes.  Author URL.
Nowak N, Szopa M, Thanabalasingham G, McDonald TJ, James TJ, Skupien J, Kiec-Wilk B, Mlynarski W, Hattersley AT, Owen KR, et al (2011). Cystatin C is not a good candidate biomarker for HNF1A MODY.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Shields BM, Hope SV, Bowman PA, Oram RA, Knight BA, Hattersley AT (2011). Measuring endogenous insulin secretion: does it matter in insulin treated patients?. Diabetes UK Annual Professional Conference 2011. 30th Mar - 1st Apr 2011.
Jones AG, Besser REJ, Shields BM, McDonald TJ, Hope SV, Oram RA, Knight BA, Hattersley AT (2011). Practical alternatives to the mixed meal tolerance test in insulin treated diabetes. Diabetes UK Annual Professional Conference 2011. 30th Mar - 1st Apr 2011.
Shields BM, McDonald TJ, Ellard S, Hyde C, Campbell M, Hattersley AT (2011). Should I test this patient for maturity onset diabetes of the young? a clinical prediction model to determine the probability of MODY.  Author URL.
Thomas NJM, Besser REJ, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011). Simple and convenient alternatives to the mixed meal tolerance test.  Author URL.
Hope SV, Jones A, Goodchild E, Shepherd M, Besser REJ, Shields B, McDonald T, Knight BA, Hattersley A (2011). URINARY C-PEPTIDE CREATININE RATIO (UCPCR) CAN BE USED AS a SCREENING TOOL TO DETECT ABSOLUTE INSULIN DEFICIENCY IN PEOPLE WITH TYPE 2 DIABETES.  Author URL.
Hope SV, Jones AG, Goodchild E, Shepherd M, Besser REJ, Shields BM, McDonald TJ, Knight BA, Hattersley AT (2011). Urinary C-Peptide Creatinine Ratio (UCPCR) can be used as a screening tool to detect absolute insulin deficiency in type 2 diabetes. Diabetes UK Annual Professional Conference 2011. 30th Mar - 1st Apr 2011.
Besser REJ, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Hammersley S, Ellard S, Hattersley AT (2011). Urinary C-peptide creatinine ratio is a practical outpatient tool in identifying MODY from type 1 diabetes in children with diabetes.  Author URL.
Rawlingson A, Knight BA, Oram R, McDonald TJ, Shields BM, Hattersley AT (2010). A novel method for the assessment of insulin physiology: urinary C-peptide creatinine ratio can be used to assess insulin sensitivity and beta cell function in non-diabetic subjects.  Author URL.
Jones AG, Hope SV, Shepherd M, Shields BM, Besser REJ, Wensley KJ, Githens-Mazer G, McDonald TJ, Knight BA, Hattersley AT, et al (2010). Do patients with Long-Standing Type 2 Diabetes Develop Absolute Insulin Deficiency?.  Author URL.
Brooks AM, Shields BM, Knight BA, McDonald TJ, Mills S, Smith J, Dyer R, Paisey R, Hattersley AT (2010). Is Intensive Carbohydrate Counting Education a Treatment Option in Patients with Atypical Characteristics for Type 1 Diabetes?.  Author URL.
Hope SV, Shepherd M, Shields BM, McDonald T, Knight BA, Hattersley AT (2010). Patients with long-standing type 2 diabetes can develop absolute insulin deficiency.  Author URL.
Besser REJ, Shepherd MH, McDonald TJ, Shields BM, Colclough KJ, Githens-Mazer G, Wensley KJ, Knight BA, Ellard S, Hattersley AT, et al (2010). Postal Urinary C-Peptide Creatinine Ratio Discriminates Long Duration Type 1 Diabetes from HNF1A MODY.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Wensley KJ, Githens-Mazer G, Shields BM, Knight BA, Hattersley AT (2010). Serum Measurement of Endogenous C-Peptide after a Mixed Meal can be Replaced with a Single Post Meal Urine C-Peptide Creatinine Ratio (UCPCR).  Author URL.
Shields BM, McDonald TJ, Bowman P, Jones AG, Besser REJ, Wensley KJ, Githens-Mazer G, Knight BA, Hattersley AT (2010). Urinary C-Peptide Creatinine Ratio (UCPCR) is a Reliable Measure of Endogenous Insulin Secretion, Even in Patients with Renal Impairment.  Author URL.
Besser REJ, Jones AG, McDonald TJ, Shields BM, Githens-Mazer G, Wensley K, Knight BA, Hattersley AT (2010). Urinary C-Peptide Creatinine Ratio is a Novel Non Invasive Alternative to the Inpatient Mixed Meal Tolerance Test in Young Onset Type 1 Diabetes.  Author URL.

Publications by year


In Press

Grubb A, McDonald T, Rutters F, Donnelly L, Hattersley A, Oram R, Palmer C, van der Heijden A, Carr F, Elders P, et al (In Press). A Type 1 Diabetes Genetic Risk Score can identify patients with GAD65 autoantibody positive type 2 diabetes that rapidly progress to insulin therapy. Diabetes Care Full text.
Knight AR, Taylor EL, Lukaszewski R, Winyard PG (In Press). A high-sensitivity electrochemiluminescence-based ELISA for the measurement of the oxidative stress biomarker, 3-nitrotyrosine, in human blood serum and cells. Free Radical Biology and Medicine Full text.
Williams GM, Long AE, Wilson IV, Aitken RJ, Wyatt RC, McDonald TJ, Wong FS, Hattersley AT, Williams AJK, Bingley PJ, et al (In Press). Beta cell function and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes. Diabetologia, 59(12), 2722-2726. Abstract.  Author URL.  Full text.
Shields B, McDonald T, Oram R, Hill A, Hudson M, Leete P, Pearson E, Richardson S, Morgan N, Hattersley A, et al (In Press). C-peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subsequent stable phase. Diabetes Care Full text.
Jones AG, McDonald TJ (In Press). Comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4 and -5 trials". Diabetes Obes Metab, 20(6), 1549-1550. Author URL.
Johnson MB, Flanagan SE, Martins TB, Hill HR, Hattersley AT, McDonald TJ (In Press). Low IgE is a Useful Tool to Identify STAT3 Gain-of-Function Mutations. Clin Chem, 62(11), 1536-1538. Author URL.  Full text.
Jones AG, mcdonald TJ, Shields BM, Hill AV, Hyde CJ, Knight BA, Hattersley AT (In Press). Markers of beta cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care Full text.
Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG (In Press). Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabet Med, 33(11), 1554-1558. Abstract.  Author URL.  Full text.
Shepherd M, Shields B, Hammersley S, Hudson M, McDonald TJ, Colclough K, Oram RA, Knight B, Hyde C, Cox J, et al (In Press). Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population with Monogenic Diabetes. Diabetes Care, 39(11), 1879-1888. Abstract.  Author URL.  Full text.

2018

Johnson MBJ, Patel K, De Franco E, Houghton J, McDonald T, Ellard S, Flanagan S, Hattersley A (2018). A Type 1 diabetes genetic risk score can discriminate monogenic autoimmunity with diabetes from early onset clustering of polygenic autoimmunity with diabetes. Diabetologia Full text.
Clissold RL, Fulford J, Hudson M, Shields BM, McDonald TJ, Ellard S, Hattersley AT, Bingham C (2018). Exocrine pancreatic dysfunction is common in hepatocyte nuclear factor 1β-associated renal disease and can be symptomatic. Clin Kidney J, 11(4), 453-458. Abstract.  Author URL.  Full text.
Walker GJ, Moore L, Heerasing N, Hendy P, Perry MH, McDonald TJ, Debenham T, Bethune R, Bewshea C, Hyde C, et al (2018). Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Aliment Pharmacol Ther, 47(8), 1103-1116. Abstract.  Author URL.
Dennis J, Shields B, Hill A, Knight B, McDonald T, Rodgers L, Weedon M, Henley W, Sattar N, Holman R, et al (2018). Precision medicine in Type 2 diabetes: Clinical markers of insulin resistance are associated with altered short and long-term glycemic response to DPP4-inhibitor therapy. Diabetes Care Full text.
Teare HJA, de Masi F, Banasik K, Barnett A, Herrgard S, Jablonka B, Postma JWM, McDonald TJ, Forgie I, Chmura PJ, et al (2018). The governance structure for data access in the DIRECT consortium: an innovative medicines initiative (IMI) project. Life Sci Soc Policy, 14(1). Abstract.  Author URL.
Patel KA, Weedon MN, Shields BM, Pearson ER, Hattersley AT, McDonald TJ, UNITED study team (2018). Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score can Exclude Individuals with Type 1 Diabetes from Inappropriate Genetic Testing for Monogenic Diabetes. Diabetes Care Author URL.

2017

Hammersley SE, Bolt RL, Hill AV, McDonald TJ, Oram RA, Hattersley AT (2017). A novel patient focused approach enables study participation and aids recruitment rate in Type 1 diabetes research.  Author URL.
Oram RA, Leete P, Shields B, Richardson S, Hill A, McDonald T, Morgan N, Hattersley A (2017). C-peptide measurements support the existence of two distinct subtypes of Type 1 diabetes as defined by pancreatic immunopathology.  Author URL.
Dennis JM, Shields BM, Henley WE, Knight BA, McDonald TJ, Hill AV, Weedon MN, Rodgers LR, Hattersley AT, Jones AG, et al (2017). Clinical markers of insulin resistance predict reduced glycaemic response with DPP4-inhibitors: a MASTERMIND stratified medicine study.  Author URL.
Shields B, Richardson S, Oram R, Leete P, Hill A, McDonald T, Morgan N, Hattersley A (2017). Cross-sectional c-peptide data and histological analysis of pancreas samples suggest two phases of beta cell decline in Type 1 diabetes.  Author URL.  Full text.
Chakera AJ, McDonald TJ, Knight BA, Vaidya B, Jones AG (2017). Current laboratory requirements for adrenocorticotropic hormone and renin/aldosterone sample handling are unnecessarily restrictive. Clin Med (Lond), 17(1), 18-21. Abstract.  Author URL.  Full text.
Grubb AL, Patel KA, Oram RA, Hill AV, Angwin C, McDonald TJ, Weedon MN, Hattersley AT, Shields BV, Jones AG, et al (2017). Development of a risk calculator to identify patients with Type 1 diabetes who will require early insulin therapy.  Author URL.
Dawed AY, Mari A, McDonald TJ, Hong MG, Sharma S, Robertson NR, Mahajan A, Walker M, Gough S, Zhou K, et al (2017). GLP-1 receptor variants markedly differentiate glycaemic response to GLP-1 receptor agonists: a DIRECT study.  Author URL.
Shields B, Shepherd M, Hudson M, McDonald T, Colclough K, Peters J, Knight B, Hyde C, Ellard S, Pearson E, et al (2017). Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care Full text.
Davidson J, McDonald T, Sutherland C, Mostazir M, VanAalten L, Wilkin T (2017). Proinsulin is stable at room temperature for 24 hours in EDTA: a clinical laboratory analysis (adAPT 3). PLoS One, 12(4). Abstract.  Author URL.  Full text.
Hope SV, Knight BA, Shields BM, Hill A, Choudhary P, Strain WD, Hattersley AT, McDonald TJ, Jones G (2017). RANDOM NON-FASTING C-PEPTIDE CAN BE USED AS a RISK ASSESSMENT TOOL FOR HYPOGLYCAEMIA IN ELDERLY NSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES.  Author URL.
Hope SV, Knight BA, Shields BM, Hill AV, Choudhary P, Strain WD, McDonald TJ, Jones AG (2017). Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia Full text.
McDonald TJ, Besser RE, Perry M, Babiker T, Knight BA, Shepherd MH, Ellard S, Flanagan SE, Hattersley AT (2017). Screening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement. Diabetologia, 60(11), 2168-2173. Abstract.  Full text.
(2017). Tests aiding diagnosis of monogenic diabetes. Practical Diabetes, 34(6), 217-220a.

2016

Oram RA, Patel K, Hill A, Shields B, McDonald TJ, Jones A, Hattersley AT, Weedon MN (2016). A Type 1 Diabetes Genetic Risk Score can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes Care, 39(3), 337-344. Abstract.  Author URL.  Full text.
Perry M, O'Connor J, James AJ, Cudmore AP, Lewis AV, Salzmann MB, McDonald TJ (2016). A cautionary tale: Unforeseen consequences of lean processing in a blood sciences laboratory. Clin Biochem, 49(16-17), 1311-1312. Author URL.
Juszczak A, James TJ, McDonald TJ, Vaxillaire M, Klimes I, Malecki MT, Hansen T, Njolstad PR, Tuomi T, Gloyn AL, et al (2016). Assessing the likely function of HNF1A missense variants using CRP and allele frequency data.  Author URL.
Patel KA, Oram RA, Mcdonald TJ, Hudson M, Colclough K, Ellard S, Weedon MN, Pearson EZ, Hattersley AT (2016). Classifying the unclassified using Type 1 diabetes genetic risk score: patients with young onset diabetes who are islet autoantibody negative and have preserved c-peptide.  Author URL.
McDonald TJ, Perry MH (2016). Detection of C-Peptide in Urine as a Measure of Ongoing Beta Cell Function. Methods Mol Biol, 1433, 93-102. Abstract.  Author URL.
Dawed AY, Jones AG, McDonald TJ, Walker M, Mari A, Franks PW, Pearson ER, Project IMI-DIRECT (2016). Determinants of glucagon secretion in prediabetes and recently diagnosed type 2 diabetes: an IMI-DIRECT study.  Author URL.
Seelig E, Timper K, Falconnier C, Stoeckli R, Bilz S, Oram R, McDonald TJ, Donath MY (2016). Interleukin-1 antagonism in type 1 diabetes of long duration. Diabetes Metab, 42(6), 453-456. Author URL.
Oram RA, Hammersley S, Hill A, Shields B, Hattersley A, McDonald T (2016). Longitudinal study of extremely low c-peptide: evidence for persistent beta cells in all people with Type 1 diabetes.  Author URL.
McDonald TJ, Besser REJ, Perry MH, Babiker T, Hattersley AT (2016). Newborn screening by blood spot glucose can diagnose neonatal diabetes at day 5 of life. DIABETIC MEDICINE, 33, 73-73. Author URL.
Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG (2016). Random non-fasting c-peptide provides an accurate measure of endogenous insulin secretion for clinical practice.  Author URL.
Umapathysivam MM, McDonald T, Humphreys S, Neville M, Gloyn AL, McCarthy MI, Hattersley AT, Karpe F, Frayling TM (2016). Strategies for improving statistical power for detailed physiological characterisation of individuals with type 2 diabetes-associated variants.  Author URL.
Peters JL, Anderson R, Shields BM, King S, Hudson M, Shepherd M, McDonald TJ, Pearson E, Hattersley AT, Hyde C, et al (2016). Strategies to identify individuals with MODY: results of a health economic model.  Author URL.
Craig ZV, Hill AV, McDonald TJ, Hattersley AT, Jones AG, Shields BM (2016). Time to change the HbA1c cut-off for prediabetes.  Author URL.

2015

Weedon MN, Hill AV, McDonald TJ, Patel KA, Jones A, Hattersley AT, Oram R (2015). A novel inexpensive test can discriminate between Type 1 and Type 2 diabetes.  Author URL.
Parfitt C, Church D, Armston A, Couchman L, Evans C, Wark G, McDonald TJ (2015). Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues. CLINICAL BIOCHEMISTRY, 48(18), 1354-1357. Author URL.
Mcdonald TJ, Parfitt C, Armston A, Church D, Couchman L, Evans C, Wark G (2015). Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues.  Author URL.
Veale DA, McCulloch RW, McDonald TJ, Cudmore A, Parfitt C, O'Connor J, Kerr JP (2015). Current use of nephelometric quantification of serum free light chains (FLCs) in the management of plasma cell dyscrasias, and the potential benefits of point-of-care testing.  Author URL.
Perry M, Bewshea C, Brown R, So K, Ahmad T, McDonald T (2015). Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. Ann Clin Biochem, 52(Pt 6), 672-674. Abstract.  Author URL.
Jones AG, Hill AV, Bolt R, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2015). Insulin resistance and high fasting glucose are associated with reduced glycaemic response to dipeptidyl peptidase 4 (DPP-4) inhibitor therapy.  Author URL.
McDonald TJ, Oram RA, Vaidya B (2015). Investigating hyperkalaemia in adults. BMJ, 351 Author URL.
Hope SV, McDonald TJ, Hill AV, Strain WD, Hattersley AT (2015). Low c-peptide is associated in insulin-treated patients with hypoglycaemia unawareness as well as hypoglycaemia frequency.  Author URL.
Oram RA, McDonald TJ, Shields BM, Hudson MM, Shepherd MH, Hammersley S, Pearson ER, Hattersley AT, UNITED Team (2015). Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care, 38(2), 323-328. Abstract.  Author URL.  Full text.
McDonald TJ, Oram RA, Vaidya B (2015). RATIONAL TESTING Investigating hyperkalaemia in adults. BMJ-BRITISH MEDICAL JOURNAL, 351 Author URL.
Rodgers LR, Pearson ER, Angwin CD, Hammersley S, McDonald TJ, Shields BM, Hattersley AT, Jones AG, Consortium M (2015). Response to glucose lowering therapy can be assessed by a brief period of treatment withdrawal: a MASTERMIND study.  Author URL.
(2015). Systolic blood pressure control among individuals with type 2 diabetes: a comparative effectiveness analysis of three interventions. American Journal of Hypertension, 28(8), 995-1009. Abstract.
Chapman DP, Gooding KM, McDonald TJ, Anning CM, Pamphilon N, Ball C, Casanova F, Shore AC (2015). Using clinical characteristics to account for variation of urinary creatinine excretion improves the accuracy of the albumin to creatinine ratio (ACR) to identify individuals with microalbuminuria.  Author URL.

2014

Oram RA, McDonald TJ, Shields BM, Pearson ER, Hattersley AT, Team UNITEDR (2014). A large, population-based study demonstrates that most people with long duration Type 1 diabetes are insulin microsecretors and produce their own endogenous insulin.  Author URL.
Flanagan SE, Haapaniemi E, Russell MA, McDonald TJ, Barton J, Murphy NP, Seppanen M, Milenkovic T, Heiskanen K, Lernmark A, et al (2014). A novel syndrome of early-onset type 1 diabetes and multi-organ autoimmunity caused by activating germline mutations in STAT3.  Author URL.
(2014). Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nature Genetics, 46(8), 812-814. Abstract.
Flanagan SE, Haapaniemi E, Russell MA, Caswell R, Allen HL, De Franco E, McDonald TJ, Rajala H, Ramelius A, Barton J, et al (2014). Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet, 46(8), 812-814. Abstract.  Author URL.  Full text.
Shields BM, Hudson M, Shepherd M, Oram R, McDonald TJ, Ellard S, Pearson ER, Hattersley AT, Team UNITED (2014). Comparison of screening using clinical criteria and biomarkers to identify maturity-onset diabetes of the young (MODY) in a community based setting.  Author URL.
Jones AG, Shields BM, Hill AV, McDonald TJ, Knight BA, Hattersley AT (2014). Defining good response to glucose lowering therapy: different definitions identify different individuals and associated characteristics.  Author URL.
McDonald TJ, Warren RE (2014). Diagnostic confusion? Repeat HbA1c for the diagnosis of diabetes. DIABETIC MEDICINE, 31, 72-72. Author URL.
McDonald TJ, Warren R (2014). Diagnostic confusion? Repeat HbA1c for the diagnosis of diabetes. Diabetes Care, 37(6), e135-e136. Author URL.
Vestergaard H, Gupta R, Herrgård S, Heymans MW, Perry MH, Rauh S, Siloaho M, Teare HJA, Thorand B, Bell J, et al (2014). Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: Rationale and design of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 57(6), 1132-1142. Abstract.
Koivula RW, Heggie A, Barnett A, Cederberg H, Hansen TH, Koopman AD, Ridderstråle M, Rutters F, Vestergaard H, Gupta R, et al (2014). Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia
(2014). Effect of the holiday season in patients with diabetes: Glycemia and lipids increase postholiday, but the effect is small and transient. Diabetes Care, 37(5).
Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, Brown RJ, Hattersley AT, McDonald TJ (2014). Erratum to: the majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 57(1). Author URL.
Myngheer N, Allegaert K, Hattersley A, McDonald T, Kramer H, Ashcroft FM, Verhaeghe J, Mathieu C, Casteels K (2014). Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes. Diabetes Care, 37(12), 3333-3335. Abstract.  Author URL.
Oram RA, Brooks AM, Forbes S, Eckoldt S, Smith RM, Choudhary P, Rosenthal MJ, Johnson P, Rutter MK, Burling KA, et al (2014). Home urine C-peptide creatinine ratio can be used to monitor islet transplant function. Diabetes Care, 37(6), 1737-1740. Abstract.  Author URL.
Jones AG, McDonald TJ, Hill AV, Stewart J, Shields BM, Knight BA, Hattersley AT (2014). Markers of beta cell failure are associated with reduced glycaemic response to GLP-1 agonists in Type 2 diabetes.  Author URL.
McDonald TJ, Oram R, Shields B, Pearson E, Hattersley A (2014). Most people with long duration of type 1 diabetes are insulin microsecretors and produce their own endogenous insulin.  Author URL.
Shepherd M, Shields B, Knight B, Weinand-Barnett S, Fox CJ, McDonald TJ, Hattersley AT (2014). Patients with Type 2 diabetes treated with analogue insulin require 40% more insulin to achieve the same level of HbA1c than those on non-analogue insulin.  Author URL.
Aitken RJ, Wilson IV, Long AE, Williams AJK, McDonald TJ, Gillespie KM, Wong FS, Hattersley AT, Bingley PJ (2014). Residual beta cell function in long-standing childhood onset Type 1 diabetes. DIABETIC MEDICINE, 31, 19-20. Author URL.
Bingley PJ, Aitken RJ, Wilson IV, Long AE, Williams AJK, McDonald T, Wong S, Hattersley AT, Gillespie KM (2014). Residual beta cell function in long-standing childhood onset type 1 diabetes.  Author URL.
Hamilton AJ, Bingham C, McDonald TJ, Cook PR, Caswell RC, Weedon MN, Oram RA, Shields BM, Shepherd M, Inward CD, et al (2014). The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a β cell phenotype. J Med Genet, 51(3), 165-169. Abstract.  Author URL.  Full text.
Adamson K, Nayak AU, Khurana R, Hunter SJ, Ali A, Au S, Ryder REJ (2014). The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study. Diabetic Medicine, 31(4), 403-411. Abstract.
McDonald TJ (2014). The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 57(1), 187-191. Abstract.

2013

Hudson MM, Shepherd M, Oram RA, McDonald TJ, Ellard S, Shields BM, Hattersley AT, Team UR (2013). A population-based approach to genetic testing defines the prevalence of maturity onset diabetes of the young (MODY) in patients with diabetes diagnosed under 30 years as 3%.  Author URL.
Jones AG, Hill AV, Stewart J, Githens-Mazer G, Shields BM, McDonald TJ, Knight BA, Hattersley AT (2013). Baseline HbA1c is the major clinical predictor of glycaemic response to incretin based agents in Type 2 diabetes. DIABETIC MEDICINE, 30, 164-164. Author URL.
Nowak N, Szopa M, Thanabalasingham G, McDonald TJ, Colclough K, Skupien J, James TJ, Kiec-Wilk B, Kozek E, Mlynarski W, et al (2013). Cystatin C is not a good candidate biomarker for HNF1A-MODY. ACTA DIABETOLOGICA, 50(5), 815-820. Author URL.
(2013). Diabetes Mellitus. In  (Ed) The Immunoassay Handbook, 783-794.
Besser REJ, Shields BM, Hammersley SE, Colclough K, McDonald TJ, Gray Z, Heywood JJN, Barrett TG, Hattersley AT (2013). Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes. Pediatr Diabetes, 14(3), 181-188. Abstract.  Author URL.
Mericq V, Hassing J, Richmond EJ, Martin WR, Acerini C, Kaulfers AM, Flynn DP, Popovic J, Sperling MA, Hussain K, et al (2013). Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: Expanding the clinical phenotype. Diabetologia, 56(1), 218-221.
Flanagan SE, Mackay DJG, Greeley SAW, McDonald TJ, Mericq V, Hassing J, Richmond EJ, Martin WR, Acerini C, Kaulfers AM, et al (2013). Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: expanding the clinical phenotype. Diabetologia, 56(1), 218-221. Author URL.
Oram RA, McDonald TJ, Vaidya B (2013). Investigating hypokalaemia. BMJ, 347 Author URL.
Jones AG, Hill AV, Stewart J, Shields BM, McDonald TJ, Knight BA, Hattersley AT (2013). Markers of insulin resistance and beta cell function do not predict response to incretin based treatments in type 2 diabetes.  Author URL.
McDonald TJ, Ellard S (2013). Maturity onset diabetes of the young: identification and diagnosis. Ann Clin Biochem, 50(Pt 5), 403-415. Abstract.  Author URL.
Steele AM, Wensley KJ, Brewer E, Shields BM, Hattersley AT, McDonald TJ (2013). Preanalytical sample handling of venous blood: How to ensure your glucose measurement is accurate and reliable. Practical Diabetes, 30(3), 128-131. Abstract.
Hammersley S, Oram R, Shepherd M, Moudiotis C, Fraser B, Mallam K, Cox J, Smith B, McDonald TJ, Besser REJ, et al (2013). Prevalence of non-Type 1 diabetes in paediatric diabetes.  Author URL.
McDonald TJ (2013). The Immunoassay Handbook. In Wild D (Ed) The Immunoassay Handbook, Gulf Professional Publishing. Abstract.
Thong KY, Mcdonald TJ, Hattersley AT, Blann AD, Ramtoola S, Duncan C, Carr S, Adamson K, Nayak AU, Khurana R, et al (2013). The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study. Diabetic Medicine
Oram RA, McDonald TJ, Jones AG, Besser REJ, Hattersley AT (2013). The majority of patients with over five years of Type 1 diabetes are insulin microsecretors and have functioning beta cells.  Author URL.  Full text.
(2013). Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabetic Medicine, 30(11), 1342-1348. Abstract.
Hope SV, Jones AG, Goodchild E, Shepherd M, Besser REJ, Shields B, McDonald T, Knight BA, Hattersley A (2013). Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabet Med, 30(11), 1342-1348. Abstract.  Author URL.  Full text.
Hope SV, Jones AG, Shepherd M, Shields B, Strain D, McDonald T, Knight BA, Hattersley AT (2013). Urinary C-peptide creatinine ratio to detect absolute insulin deficiency in type 2 diabetes.  Author URL.
Oram RA, Rawlingson A, Shields BM, Bingham C, Besser REJ, McDonald TJ, Knight BA, Hattersley AT (2013). Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. BMJ Open, 3(12). Abstract.  Author URL.  Full text.
Oram RA, Brooks AMS, Smith R, Rutter MK, Johnson PR, Choudhary P, Rosenthal M, Forbes S, McDonald TJ, Hattersley AT, et al (2013). Urine c-peptide creatinine ratio can be used for home monitoring of islet transplant function. DIABETIC MEDICINE, 30, 87-87. Author URL.

2012

Knight BA, Hattersley AT (2012). Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocrine Disorders, 12 Abstract.  Full text.
McDonald TJ, Perry MH, Peake RWA, Pullan NJ, O'Connor J, Shields BM, Knight BA, Hattersley AT (2012). EDTA improves stability of whole blood C-peptide and insulin to over 24 hours at room temperature. PLoS One, 7(7). Abstract.  Author URL.
Shields BM, McDonald TJ, Owen KR, Malecki MT, Besser REJ, Jones AG, Ellard S, Hattersley AT (2012). Integration of biomarkers and clinical characteristics provides the best method for identifying patients with MODY.  Author URL.
(2012). Lipoprotein composition in HNF1A-MODY: Differentiating between HNF1A-MODY and Type 2 diabetes. Clinica Chimica Acta, 413(9-10), 927-932. Abstract.
McDonald TJ, McEneny J, Pearson ER, Thanabalasingham G, Szopa M, Shields BM, Ellard S, Owen KR, Malecki MT, Hattersley AT, et al (2012). Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes. Clin Chim Acta, 413(9-10), 927-932. Abstract.  Author URL.
Shields BM, McDonald TJ, Ellard S, Campbell MJ, Hyde C, Hattersley AT (2012). The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia, 55(5), 1265-1272. Abstract.  Author URL.
Thomas NJ, Shields BM, Besser REJ, Jones AG, Rawlingson A, Goodchild E, Leighton C, Bowman P, Shepherd M, Knight BA, et al (2012). The impact of gender on urine C-peptide creatinine ratio interpretation. Ann Clin Biochem, 49(Pt 4), 363-368. Abstract.  Author URL.
Besser REJ, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2012). The impact of insulin administration during the mixed meal tolerance test. Diabet Med, 29(10), 1279-1284. Abstract.  Author URL.
Oram RA, Shepherd MH, Hudson M, Sanders T, Tiley S, Hammersley S, Shields B, McDonald TJ, Knight BA, Besser REJ, et al (2012). The prevalence of endogenous insulin production in a cohort of adults with type 1 diabetes.  Author URL.
(2012). Using highly sensitive C-reactive protein measurement to diagnose MODY in a family with suspected type 2 diabetes. BMJ Case Reports Abstract.
Besser REJ, Jones J, McDonald TJ, Smith R, Shepherd MH, Hattersley AT (2012). Using highly sensitive C-reactive protein measurement to diagnose MODY in a family with suspected type 2 diabetes. BMJ case reports, 2012 Abstract.
Bowman P, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2012). Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes. Diabet Med, 29(1), 90-93. Abstract.  Author URL.

2011

(2011). A novel case of a raised testosterone and LH in a young man. Clinica Chimica Acta, 412(21-22), 1999-2001. Abstract.
Nowak N, Szopa M, Thanabalasingham G, McDonald TJ, James TJ, Skupien J, Kiec-Wilk B, Mlynarski W, Hattersley AT, Owen KR, et al (2011). Cystatin C is not a good candidate biomarker for HNF1A MODY.  Author URL.
McDonald TJ, Shields BM, Lawry J, Owen KR, Gloyn AL, Ellard S, Hattersley AT (2011). High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care, 34(8), 1860-1862. Abstract.  Author URL.
McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P, Williams A, Hattersley AT, Ellard S (2011). Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med, 28(9), 1028-1033. Abstract.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Shields BM, Hope SV, Bowman PA, Oram RA, Knight BA, Hattersley AT (2011). Measuring endogenous insulin secretion: does it matter in insulin treated patients?. Diabetes UK Annual Professional Conference 2011. 30th Mar - 1st Apr 2011.
Jones AG, Besser REJ, Shields BM, McDonald TJ, Hope SV, Oram RA, Knight BA, Hattersley AT (2011). Practical alternatives to the mixed meal tolerance test in insulin treated diabetes. Diabetes UK Annual Professional Conference 2011. 30th Mar - 1st Apr 2011.
(2011). Response to comment on: McDonald et al. High-Sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care 2011;34: 1860-1862. Diabetes Care, 34(12).
Shields BM, McDonald TJ, Ellard S, Hyde C, Campbell M, Hattersley AT (2011). Should I test this patient for maturity onset diabetes of the young? a clinical prediction model to determine the probability of MODY.  Author URL.
Thomas NJM, Besser REJ, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011). Simple and convenient alternatives to the mixed meal tolerance test.  Author URL.
Hope SV, Jones A, Goodchild E, Shepherd M, Besser REJ, Shields B, McDonald T, Knight BA, Hattersley A (2011). URINARY C-PEPTIDE CREATININE RATIO (UCPCR) CAN BE USED AS a SCREENING TOOL TO DETECT ABSOLUTE INSULIN DEFICIENCY IN PEOPLE WITH TYPE 2 DIABETES.  Author URL.
Hope SV, Jones AG, Goodchild E, Shepherd M, Besser REJ, Shields BM, McDonald TJ, Knight BA, Hattersley AT (2011). Urinary C-Peptide Creatinine Ratio (UCPCR) can be used as a screening tool to detect absolute insulin deficiency in type 2 diabetes. Diabetes UK Annual Professional Conference 2011. 30th Mar - 1st Apr 2011.
Besser REJ, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S, Hattersley AT (2011). Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care, 34(2), 286-291. Abstract.  Author URL.
Besser REJ, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Hammersley S, Ellard S, Hattersley AT (2011). Urinary C-peptide creatinine ratio is a practical outpatient tool in identifying MODY from type 1 diabetes in children with diabetes.  Author URL.
Besser REJ, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011). Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care, 34(3), 607-609. Abstract.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Shields BM, Hope SV, Bowman P, Oram RA, Knight BA, Hattersley AT (2011). Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. Diabet Med, 28(9), 1034-1038. Abstract.  Author URL.

2010

Rawlingson A, Knight BA, Oram R, McDonald TJ, Shields BM, Hattersley AT (2010). A novel method for the assessment of insulin physiology: urinary C-peptide creatinine ratio can be used to assess insulin sensitivity and beta cell function in non-diabetic subjects.  Author URL.
Jones AG, Hope SV, Shepherd M, Shields BM, Besser REJ, Wensley KJ, Githens-Mazer G, McDonald TJ, Knight BA, Hattersley AT, et al (2010). Do patients with Long-Standing Type 2 Diabetes Develop Absolute Insulin Deficiency?.  Author URL.
Brooks AM, Shields BM, Knight BA, McDonald TJ, Mills S, Smith J, Dyer R, Paisey R, Hattersley AT (2010). Is Intensive Carbohydrate Counting Education a Treatment Option in Patients with Atypical Characteristics for Type 1 Diabetes?.  Author URL.
Hope SV, Shepherd M, Shields BM, McDonald T, Knight BA, Hattersley AT (2010). Patients with long-standing type 2 diabetes can develop absolute insulin deficiency.  Author URL.
Besser REJ, Shepherd MH, McDonald TJ, Shields BM, Colclough KJ, Githens-Mazer G, Wensley KJ, Knight BA, Ellard S, Hattersley AT, et al (2010). Postal Urinary C-Peptide Creatinine Ratio Discriminates Long Duration Type 1 Diabetes from HNF1A MODY.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Wensley KJ, Githens-Mazer G, Shields BM, Knight BA, Hattersley AT (2010). Serum Measurement of Endogenous C-Peptide after a Mixed Meal can be Replaced with a Single Post Meal Urine C-Peptide Creatinine Ratio (UCPCR).  Author URL.
Shields BM, McDonald TJ, Bowman P, Jones AG, Besser REJ, Wensley KJ, Githens-Mazer G, Knight BA, Hattersley AT (2010). Urinary C-Peptide Creatinine Ratio (UCPCR) is a Reliable Measure of Endogenous Insulin Secretion, Even in Patients with Renal Impairment.  Author URL.
Besser REJ, Jones AG, McDonald TJ, Shields BM, Githens-Mazer G, Wensley K, Knight BA, Hattersley AT (2010). Urinary C-Peptide Creatinine Ratio is a Novel Non Invasive Alternative to the Inpatient Mixed Meal Tolerance Test in Young Onset Type 1 Diabetes.  Author URL.

2009

(2009). Health promotion strategies for the "boomer" generation: Wellness for the mature worker. American Journal of Health Promotion, 23(3), 1-9.
McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB, Hattersley AT (2009). Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem, 55(11), 2035-2039. Abstract.  Author URL.

2008

Anand S, Cracknell B, Cukierman-Yaffe T, Gafni A, Guyatt G, Hall S, Kaszyca J, Lonn E, McLeod D, Read K, et al (2008). Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine, 358(24), 2545-2559. Abstract.

2006

Miller A, Edington DW (2006). Association of healthcare costs with per unit body mass index increase. Journal of Occupational and Environmental Medicine, 48(7), 668-674. Abstract.
(2006). Participation in employer-sponsored wellness programs before and after retirement. American Journal of Health Behavior, 30(1), 27-38. Abstract.

2005

(2005). BMI, physical activity, and health care utilization/costs among medicare retirees. Obesity Research, 13(8), 1450-1457. Abstract.

2004

Edington DW (2004). Association of Additional Health Risks on Medical Charges and Prevalence of Diabetes Within Body Mass Index Categories. American Journal of Health Promotion, 18(3), 264-268. Abstract.
Napier D, Galante S, Smith T, Edington DW (2004). Comparing excess costs across multiple corporate populations. Journal of Occupational and Environmental Medicine, 46(9), 937-945. Abstract.
(2004). Relationship of Body Mass Index and Physical Activity to Health Care Costs among Employees. Journal of Occupational and Environmental Medicine, 46(5), 428-436. Abstract.

2003

(2003). Association Between Wellness Score from a Health Risk Appraisal and Prospective Medical Claims Costs. Journal of Occupational and Environmental Medicine, 45(10), 1049-1057. Abstract.
Musich S, McDonald T, Hirschland D, Edington DW (2003). Erratum: Examination of risk status transitions among active employees in a comprehensive worksite health promotion program (Journal of Occupational and Environmental Medicine (April)). Journal of Occupational and Environmental Medicine, 45(6).
(2003). Examination of risk status transitions among active employees in a comprehensive worksite health promotion program. Journal of Occupational and Environmental Medicine, 45(4), 393-399. Abstract.
Edington DW (2003). Pattern of Medical Charges after Quitting Smoking among those with and without Arthritis, Allergies, or Back Pain. American Journal of Health Promotion, 18(2), 133-142. Abstract.
(2003). The relationship between National Heart, Lung, and Blood Institute weight guidelines and concurrent medical costs in a manufacturing population. American Journal of Health Promotion, 17(3), 183-189. Abstract.

2002

Musich S, McDonald T, Hirschland D, Edington DW (2002). Excess healthcare costs associated with excess health risks in diseased and non-diseased Health Risk Appraisal participants. Disease Management and Health Outcomes, 10(4), 251-258. Abstract.
Edington DW (2002). Influence of participation in a worksite health-promotion program on disability days. Journal of Occupational and Environmental Medicine, 44(8), 776-780. Abstract.

2001

(2001). Changes in health risks among the participants in the United Auto Workers - General Motors lifesteps health promotion program. American Journal of Health Promotion, 16(1), 7-15. Abstract.
(2001). Internal associations among health-risk factors and risk prevalence. American Journal of Health Behavior, 25(4), 407-417. Abstract.
(2001). Self-reported utilization of preventive health services by retired employees age 65 and older. Journal of the American Geriatrics Society, 49(12), 1665-1672. Abstract.

Timothy_McDonald Details from cache as at 2019-01-22 23:45:42

Refresh publications

External Engagment and Impact

Awards

NIHR Research Poster presentation prize- NIHR faculty meeting 2014

Diabetes UK Lily Clinical Science Poster Award – Diabetes UK Professional conference 2016

The ACB Professors’ Prize Lecture- The Association of Clinical Biochemistry and Laboratory Medicine research contribution prize. FOCUS national conference 2016

NIHR CSO Clinical Research Fellow 2013 (four years funding)

The Department of Health Young Healthcare Scientist of the Year 2012 (London)

The University of Exeter Impact Award- finalist Student Impact Award 2011 (Exeter)

The Association of Clinical Biochemists regional Young Researcher Award 2010 First prize for best presentation and research paper (Swansea)

Regional NHS audit meeting, 2008 (Weston-Super-mare). Awarded second prize in clinical audit competition

The Association of Clinical Biochemistry regional meeting, 2008 (Gloucester). Awarded first prize Siemens award for best research paper presentation.


Committee/panel activities

Association of Clinical Biochemistry South-West Regional Tutor


Invited lectures

Identifying unusual diabetes! Association of Biochemists Ireland: Dublin 2014

Precision Medicine- getting the diagnosis right. KEM Pune, India 2015.

Association of Clinical Biochemist Professors’ prize lecture, Warick 2016

C-peptide: time to think again? Bristol Diabetes Association. Bristol 213

The analyser will see you now!. Association of Clinical Biochemists. midlands scientific meeting, Birmingham 2013

Systematic approach to correct genetic diagnosis. Diabetes UK, Manchester 2013

Using biomarkers to identify MODY in our clinics. Advances in the Science and Care of Diabetes. Winthrop Hospital Symposium, New York. May 2012

Maturity Onset Diabetes of the Young (MODY). Correct classification with the use of biomarkers. ACB FOCUS national conference. Harrogate 2011

Urine C-peptide creatinine ratio: a new marker of insulin secretion? KEM, Pune, India 201

Diabetes autoantibodies can discriminate MODY from Type 1 diabetes. South West Peninsula Immunology symposium, Dartington Hall. 2010

Getting the diabetes right, Urine C-peptide creatinine ratio. Association of Clinical Biochemists SWW regional scientific meeting, Exeter 2010

Teaching

Supervision / Group

Back | Edit Profile